Progressive Supranuclear Palsy (PSP) is a rare, progressive, neurodegenerative disease that imposes a substantial physical, emotional and financial burden on both patients and their families.
PSP affects 5-6 people per 100,000. Although some medications may help relieve symptoms associated with the condition, none have been proven to slow or stop the progression of the disease itself. Researchers are working hard to develop new investigational treatments for PSP through clinical trials.
In the PASSPORT clinical trial we want to find out whether our investigational study drug will slow the progression of PSP.
FIND OUT MOREThis link will take you away from a Biogen regulated website.
Proceed